STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
343
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · no price filed
What the filings say about AHR
Insiders, 180 days
-$1.7M net sold
2 sellers · 20% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$188.9K
2 notices
American Healthcare REIT insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, American Healthcare REIT, Inc. insiders sold a net $1.7M of stock across 12 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 24, 2026.
The trade is 3.9% of the 51,617 shares held after it.
No other insider sold within 30 days.
343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC & Secretary Foster Mark E. sold about $110.8K of AHR under a 10b5-1 plan on Sep 1, 2026; 343 funds added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 16.4% of the 152,700 shares held after it.
1 other insider sold within 30 days.
343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer PEAY BRIAN sold about $1.3M of AHR on Jun 26, 2026; 1 other insider sold within 30 days and 343 funds added in the latest 13F quarter.
4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 1, 2026.
The trade is 4.7% of the 52,995 shares held after it.
1 other insider sold within 30 days.
343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC & Secretary Foster Mark E. sold about $121.5K of AHR on Jun 24, 2026; 1 other insider sold within 30 days and 343 funds added in the latest 13F quarter.
3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 25, 2026.
The trade is 3.6% of the 55,495 shares held after it.
1 other insider sold within 30 days.
343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC & Secretary Foster Mark E. sold about $96.6K of AHR on Jun 1, 2026; 1 other insider sold within 30 days and 343 funds added in the latest 13F quarter.
12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
AHR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Mark Foster
Filed 2026-09-25
$78.1K
Mark Foster
Filed 2026-09-01
$110.8K
Brian Peay
Filed 2026-06-26
$1.3M
Mark Foster
Filed 2026-06-24
$121.5K
AHR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Dunham Real Estate Stock Fund
$3.5M position · as of 2026-07-31
4.7%
PGIM US Real Estate Fund
$17.7M position · as of 2026-06-30
4.7%
Bahl & Gaynor Small Cap Dividend ETF
$7.1M position · as of 2026-06-30
4.6%
Easterly Global Real Estate Fund
$8.1M position · as of 2026-05-31
4.4%
Nomura Real Estate Securities Fund
$3.9M position · as of 2026-06-30
4.2%
Virtus Duff & Phelps Real Estate Securities Series
$4.8M position · as of 2026-06-30
4.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Danny Prosky
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.7M
$20.6M
$2.4M
+285%
+81%
2024
$7.7M
$15.4M
$3.3M
+127%
+40%
2023
$3.8M
$3.0M
$1.5M
n/a
n/a
2022
$1.8M
$2.3M
$884.1K
n/a
n/a
2021
$2.4M
$2.4M
$1.2M
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.7M sold by insiders over 180 days, 343 funds added last quarter, $188.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AHR
FY Dec 2025
$2.3B
FY Dec 2024
$2.1B
FY Dec 2023
n/a
FY Dec 2022
$1.4B
FY Dec 2021
$1.1B
Jun 2026
$674.2M
Mar 2026
$650.8M
Dec 2025
$604.1M
Sep 2025
$572.9M
Jun 2025
$542.5M
Mar 2025
$540.6M
Dec 2024
$542.7M
Sep 2024
$523.8M
At each fiscal year end
Single quarter
Net margin, TTM
+4.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AHR
FY Dec 2025
+3.1%
FY Dec 2024
-1.7%
FY Dec 2023
n/a
FY Dec 2022
-5.2%
FY Dec 2021
-4.7%
Jun 2026
+4.5%
Mar 2026
+3.6%
Dec 2025
+2.0%
Sep 2025
+9.8%
Jun 2025
+1.8%
Mar 2025
-1.3%
Dec 2024
-5.4%
Sep 2024
-0.8%
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM AHR
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
$11.9M
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity AHR
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt AHR
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+4.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AHR
FY Dec 2025
+2.5%
FY Dec 2024
-2.0%
FY Dec 2023
-5.8%
FY Dec 2022
-4.9%
FY Dec 2021
-4.4%
Jun 2026
+4.0%
Mar 2026
+3.5%
Dec 2025
+2.5%
Sep 2025
+1.2%
Jun 2025
-1.4%
Mar 2025
-1.8%
Dec 2024
-2.0%
Sep 2024
-2.2%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AHR
FY Dec 2025
+1.4%
FY Dec 2024
-0.8%
FY Dec 2023
-1.6%
FY Dec 2022
-1.6%
FY Dec 2021
-1.4%
Jun 2026
+2.4%
Mar 2026
+2.0%
Dec 2025
+1.4%
Sep 2025
+0.6%
Jun 2025
-0.7%
Mar 2025
-0.8%
Dec 2024
-0.8%
Sep 2024
-0.8%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -24%, not meaningful
Return on invested capital AHR
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
assets or current liabilities not filed
Return on capital employed AHR
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
75.09x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing AHR
FY Dec 2025
114.78x
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
76.69x
Mar 2026
81.31x
Dec 2025
114.78x
Sep 2025
381.91x
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value AHR
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield AHR
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing AHR
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
AHR ranks highest on institutional and government (86th percentile) and growth (72nd), and lowest on insider conviction (10th), among Real Estate peers.
Profitability
59
Inputs
Return on equity+4.0% · 52 pct, sector of 230
Return on assets+2.4% · 65 pct, sector of 255
Return on invested capitaleffective tax rate -24%, not meaningful
Return on capital employedassets or current liabilities not filed
Growth
72
Inputs
Revenue growth, YoY+11.2% · 72 pct, sector of 244
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
10
Inputs
Net Form 4 buying (codes P and S), 180d-$1.6M · 21 pct, sector of 156
Insider buyers, 180d0 · 0 pct, sector of 158
Institutional and government
86
Inputs
Funds adding, latest quarter343 · 86 pct, sector of 171
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
28
Inputs
Short interest, % of float+14.7% · 5 pct, sector of 256
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+8.4% · 51 pct, sector of 212
2 not measured: Financial health, US patents
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AHR filings, in plain words
Are American Healthcare REIT insiders buying or selling AHR?
In the 180 days to 2026-10-28, American Healthcare REIT insiders were net sellers, a net $1.7M across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of AHR?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $188.9K of stock; the latest, by Mark Foster, was filed 2026-09-25.
Read the full summary
In the 180 days to 2026-10-28, American Healthcare REIT insiders were net sellers of AHR, a net $1.7M across purchases and sales reported on Form 4 by 2 sellers. 20% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $188.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.